Rothschild Investment LLC Crinetics Pharmaceuticals, Inc. Transaction History
Rothschild Investment LLC
- $1.53 Trillion
- Q3 2024
A detailed history of Rothschild Investment LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Rothschild Investment LLC holds 85 shares of CRNX stock, worth $5,008. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85
Previous 30
183.33%
Holding current value
$5,008
Previous $1.34 Million
223.21%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CRNX
# of Institutions
247Shares Held
80.3MCall Options Held
268KPut Options Held
197K-
Vanguard Group Inc Valley Forge, PA6.29MShares$370 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$367 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.11MShares$360 Million2.95% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$272 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.41MShares$260 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $3.17B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...